Condition: Influenza · Sponsor: Hoffmann-La Roche
This study consists of two parts: Part A Surveillance and Part B Transmission. The main purpose of Part A is to evaluate the prevalence of pre-dose and treatment-emergent amino acid substitutions in pediatric participants' \<12 years with influenza treated with baloxavir marboxil. Part B will include a subset of Part A participants who have household contacts (HHCs) recruited to the study. Part B will evaluate the incidence of onward influenza transmission from pediatric index participants (IPs) under 5 years of age and those aged 5 to under 12 years, treated with baloxavir marboxil, to their HHCs. Participants will no longer be enrolled to Part B Transmission as per protocol version 3.
This description comes directly from the study's public registry record.
Reference Study ID Number: CV44536 https://forpatients.roche.com/ · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Always discuss trial participation with your own doctor first.
| Central Alabama Research | Birmingham, Alabama, United States | Recruiting |
| Harrisburg Family Medical Center | Harrisburg, Arkansas, United States | Recruiting |
| Kendall South Medical Center Inc. | Miami, Florida, United States | Recruiting |
| Avanza Medical Research Center | Pensacola, Florida, United States | Recruiting |
| Tekton Research - Chamblee Georgia | Chamblee, Georgia, United States | Withdrawn |
| Tekton Research Lawrenceville | Lawrenceville, Georgia, United States | Withdrawn |
| Velocity Clinical Research at Primary Pediatrics Macon | Macon, Georgia, United States | Completed |
| Clinical Research Prime | Idaho Falls, Idaho, United States | Recruiting |
| Mishawaka Osteopathic Clinic | Mishawaka, Indiana, United States | Recruiting |
| Kentucky Pediatric Research Center | Bardstown, Kentucky, United States | Recruiting |
| Velocity Clinical Research Lafayette | Lafayette, Louisiana, United States | Recruiting |
| Velocity Clinical Research, Slidell | Slidell, Louisiana, United States | Completed |
+ 39 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06094010